Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| AstraZeneca | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To assess the acute and long-term bimodal efficacy of QTP, as an adjunct to ongoing treatment with lithium (Li) or divalproex (DIV) or lamotrigine (LAM) or any combination of the three thereof, in a group of patients with an index episode of a mixed state in BD.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| quetiapine SR | Active Comparator | quetiapine SR, 200-600mg, po, qd |
|
| quetiapine sr Placebo | Placebo Comparator | quetiapine SR placebo, 200-600mg, po qd |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| quetiapine SR | Drug | quetiapine SR, dose range 200-600mg, each night QHS for 6mos |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of Patients Whose Mood Improved According to MADRS and YMRS Scale Scores. | The primary outcome measure was assessed by 50% reduction in: 1. depression scores on the Montgomery Asberg Depression Rating Scale (MADRS), which ranges from 0 indicating no symptoms to 60 indicating most symptoms 2. mania scores on the Young Mania Rating Scale (YMRS), which ranges from 0 indicating no symptoms to 60 indicating most symptoms. | Baseline visit to week 24 |
Not provided
Not provided
Inclusion Criteria:
Male or female;
Age 18 years and older
Patients on:
Patients meeting DSM-IV TR diagnosis of bipolar disorder, I or II, as assessed using the MINI, (Sheehan et al., 1998) PLUS any ONE of criteria 5 or 6 or 7
Patients meeting DSM-IV TR diagnostic criteria for a mixed manic episode with Young Mania Rating Scale (YMRS) score>/=14 and Montgomery Asberg Depression Rating Scale (MADRS) score>/=14
Patients meeting the criteria for a manic/hypomanic episode for at least 2 days with the simultaneous presence of Young Mania Rating Scale (YMRS) score>/=14 PLUS Montgomery Asberg Depression Rating Scale (MADRS) score>/=14 ;
Patients meeting DSM-IV TR diagnostic criteria for a major depressive episode with the simultaneous presence of MADRS score>/=14 PLUS meeting the criteria for a manic/hypomanic episode for at least 2 days with the simultaneous presence of Young Mania Rating Scale (YMRS) score>/=14
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Charles Bowden, MD | University of Texas | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| The University of Texas Health Science Center at San Antonio | San Antonio | Texas | 78229 | United States |
Patients screened over a 7 day period.
Participants were recruited in our University, Center for Healthcare Services, and by televison ads between Oct 2007 and January 2011.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Quetiapine SR, 200-600mg , po, QD | mood stabilizer plus active quetiapine SR |
| FG001 | Quetiapine sr Placebo 200-600mg, po, qd | mood stabilizer plus quetiapine SR placebo |
| Title | Milestones | Reasons Not Completed | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Active Quetiapine SR | mood stabilizer plus active quetiapine sr |
| BG001 | Quetiapine SR Placebo | mood stabilizer plus quetiapine SR placebo |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Number of Patients Whose Mood Improved According to MADRS and YMRS Scale Scores. | The primary outcome measure was assessed by 50% reduction in: 1. depression scores on the Montgomery Asberg Depression Rating Scale (MADRS), which ranges from 0 indicating no symptoms to 60 indicating most symptoms 2. mania scores on the Young Mania Rating Scale (YMRS), which ranges from 0 indicating no symptoms to 60 indicating most symptoms. | Per Protocol | Posted | Number | participants | Baseline visit to week 24 |
|
10/30/2007 - 6/1/2011, 2 yrs 8 mos.
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Mood Stabilizer Plus Quetiapine SR | mood stabilizer plus active quetiapine SR |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| dry mouth | General disorders | Systematic Assessment |
Overall limitations were screen failures and lost to follow-ups which led to not reaching recruitment goals.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Charles L Bowden, MD | UTHSCSA | 210-567-5393 | BowdenC@uthscsa.edu |
Not provided
| ID | Term |
|---|---|
| D001714 | Bipolar Disorder |
| D000087122 | Mania |
| D003863 | Depression |
| ID | Term |
|---|---|
| D000068105 | Bipolar and Related Disorders |
| D019964 | Mood Disorders |
| D001523 | Mental Disorders |
| D019954 | Neurobehavioral Manifestations |
Not provided
Not provided
| ID | Term |
|---|---|
| D000069348 | Quetiapine Fumarate |
| ID | Term |
|---|---|
| D003987 | Dibenzothiazepines |
| D013841 | Thiazepines |
| D013846 | Thiepins |
| D013457 | Sulfur Compounds |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| quetiapine sr placebo | Drug | quetiapine sr placebo, dose range 200-600mg, each night QHS for 6mos |
|
| Lack of Efficacy |
|
| incarceration |
|
| BG002 | Total | Total of all reporting groups |
| Participants |
|
| Age, Continuous | Mean | Standard Deviation | years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
mood stabilizer plus quetiapine S.R. placebo
|
|
| 0 |
| 15 |
| 10 |
| 15 |
| EG001 | Mood Stabilizer Plus Quetiapine sr Placebo | mood stabilizer plus quetiapine SR placebo | 0 | 13 | 7 | 13 |
| joint pain | General disorders | Systematic Assessment |
|
| drowsiness/sedation | Investigations | Systematic Assessment |
|
| interrupted sleep | Investigations | Systematic Assessment |
|
| muscle weakness | Musculoskeletal and connective tissue disorders | Systematic Assessment |
|
| nausea | Gastrointestinal disorders | Systematic Assessment |
|
| headache | General disorders | Systematic Assessment |
|
| increased appetite | Metabolism and nutrition disorders | Systematic Assessment |
|
Not provided
Not provided
| D009461 | Neurologic Manifestations |
| D009422 | Nervous System Diseases |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D001526 | Behavioral Symptoms |
| D001519 | Behavior |
| D009930 |
| Organic Chemicals |
| D006575 | Heterocyclic Compounds, 3-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |